Earnings summaries and quarterly performance for LifeStance Health Group.
Executive leadership at LifeStance Health Group.
David Bourdon
Detailed
Chief Executive Officer
CEO
AV
Ann Varanakis
Detailed
Chief People Officer
KB
Kenneth Burdick
Detailed
Executive Chairperson
RM
Ryan McGroarty
Detailed
Chief Financial Officer and Treasurer
RP
Ryan Pardo
Detailed
Chief Legal Officer and Secretary
VP
Vaughn Paunovich
Detailed
Chief Technology Officer
Board of directors at LifeStance Health Group.
Research analysts who have asked questions during LifeStance Health Group earnings calls.
CH
Craig Hettenbach
Morgan Stanley
6 questions for LFST
Also covers: ACCD, AMWL, ARDT +10 more
JP
Jamie Perse
The Goldman Sachs Group, Inc.
4 questions for LFST
Also covers: BTSG, CON, DOCS +8 more
Kevin Caliendo
UBS
4 questions for LFST
Also covers: ACH, AHCO, ALGN +18 more
LG
Lisa Gill
JPMorgan Chase & Co.
4 questions for LFST
Also covers: AGL, CAH, CI +15 more
Richard Close
Canaccord Genuity Group
4 questions for LFST
Also covers: ACCD, AHCO, CLOV +15 more
Brian Tanquilut
Jefferies
3 questions for LFST
Also covers: ACHC, ADUS, AHCO +31 more
David Larsen
BTIG
3 questions for LFST
Also covers: ACCD, AGL, AMWL +20 more
Matthew Mardula
William Blair
3 questions for LFST
Also covers: ASTH, HCSG, MD +2 more
JS
Jack Slevin
Jefferies Financial Group Inc.
2 questions for LFST
Also covers: AGL, AMN, ASTH +10 more
PW
Peter Warendorf
Barclays
2 questions for LFST
Also covers: PGNY, TALK
Sean Dodge
RBC Capital Markets
2 questions for LFST
Also covers: BTSG, CDMO, CTLT +14 more
SD
Steve Deckert
KeyBanc
2 questions for LFST
AZ
Andrea Zayco Narvaez Alfonso
UBS
1 question for LFST
Also covers: ELAN, EVH, ZTS
JS
Jack Senft
William Blair
1 question for LFST
Also covers: AMWL, HCSG, MD +3 more
RD
Ryan Daniels
William Blair & Company, L.L.C.
1 question for LFST
Also covers: ACCD, AGL, ALHC +12 more
SD
Stephanie Davis
Barclays
1 question for LFST
Also covers: ACCD, CAH, COR +20 more
SD
Steve Dechert
KeyBanc Capital Markets
1 question for LFST
Also covers: ABCL, ABSI, CERT +2 more
Recent press releases and 8-K filings for LFST.
LifeStance Health Group Reports Strong Q4 2025 Results, Issues 2026 Guidance, and Authorizes Share Repurchase Program
LFST
Earnings
Guidance Update
Share Buyback
- LifeStance Health Group reported strong Q4 2025 revenue of $382 million, an increase of 17% year-over-year, and Adjusted EBITDA of $49 million, up 49% year-over-year, achieving its highest Adjusted EBITDA as a percentage of revenue at 12.8%. For the full year 2025, the company delivered positive net income and earnings per share, a year earlier than expected.
- For the full year 2026, the company expects revenue between $1.615 billion and $1.655 billion, and Adjusted EBITDA between $185 million and $205 million, with the midpoint representing an 11.9% margin. LifeStance also anticipates generating meaningful positive free cash flow for the full year 2026.
- The Board of Directors has authorized a share repurchase program of up to $100 million, which will be funded with cash on hand to deploy capital efficiently and create long-term shareholder value.
- Ken Burdick, the Executive Chairman, will transition to the role of non-executive chair of the LifeStance board in March 2026. The company continues to expect to reach mid-teens Adjusted EBITDA margins by fiscal year 2028.
3 days ago
LifeStance Health Group Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance
LFST
Earnings
Guidance Update
Share Buyback
- LifeStance Health Group (LFST) reported a year of outperformance in 2025, exceeding all guided metrics for both the fourth quarter and the full year. For the full year, revenue reached $1.424 billion, up 14% year-over-year, and Adjusted EBITDA was $158 million, increasing 32% year-over-year, with margins at 11.1%. The company achieved positive net income and earnings per share for the full year, a year ahead of expectations.
- Operational improvements in 2025 included a 7% improvement in clinician productivity in the second half of the year, driven by initiatives such as improved clinician scheduling, a cash incentive program, and enhanced patient access through shortened booking lead times and improved conversion rates. The company's clinician base grew by 9% to 8,040 clinicians.
- For 2026, LifeStance expects full-year revenue between $1.615 billion and $1.655 billion, Center Margin between $526 million and $550 million, and Adjusted EBITDA between $185 million and $205 million, representing an almost 1% margin expansion to 11.9% at the midpoint. The company also anticipates generating meaningful positive free cash flow for the full year 2026.
- The Board of Directors authorized a $100 million share repurchase program, to be funded with cash on hand, and M&A continues to be a priority. Additionally, LifeStance completed its EHR discovery process and decided to transition to a new best-in-class vendor, with implementation expected in 2026 and transition in 2027, involving an estimated cash use of $20 million-$30 million during this period.
3 days ago
LifeStance Health Group Reports Strong Q4 and Full-Year 2025 Results, Authorizes Share Repurchase, and Provides 2026 Guidance
LFST
Earnings
Guidance Update
Share Buyback
- LifeStance Health Group reported strong Q4 2025 revenue of $382 million, a 17% increase year-over-year, and Adjusted EBITDA of $49 million, up 49% year-over-year, achieving a 12.8% margin.
- For the full year 2025, the company delivered $1.424 billion in revenue and $158 million in Adjusted EBITDA, marking the first time as a public company with double-digit Adjusted EBITDA margins and positive net income and earnings per share, one year ahead of expectations.
- The Board of Directors authorized a share repurchase program of up to $100 million.
- For 2026, the company expects full-year revenue between $1.615 billion and $1.655 billion and Adjusted EBITDA between $185 million and $205 million.
- LifeStance is initiating the implementation of a new EHR system in 2026, with an estimated cost of $20 million-$30 million over 2026-2027, and anticipates reaching mid-teens Adjusted EBITDA margins by fiscal year 2028.
3 days ago
LifeStance Health Group Announces Q4 and Full-Year 2025 Results
LFST
Earnings
Revenue Acceleration/Inflection
- LifeStance Health Group reported Q4 2025 revenue of $382.2 million, an increase of 17% year-over-year, and full-year revenue of $1,424.3 million, up 14% year-over-year.
- The company achieved a Q4 Center Margin of $126.3 million, or 33.0% as a percentage of revenue, and Q4 Adjusted EBITDA of $48.8 million, or 12.8% as a percentage of revenue.
- Total clinicians reached 8,040, representing a 9% year-over-year increase, with 44 net clinician adds in Q4 2025.
- Q4 visit volumes grew 18% year-over-year to 2.4 million, contributing to 9.0 million full-year visit volumes, an increase of 14% year-over-year.
- LifeStance ended Q4 2025 with a cash position of $248.6 million.
3 days ago
LifeStance Health Group Announces Q4 and Full Year 2025 Results and 2026 Outlook
LFST
Earnings
Guidance Update
Share Buyback
- LifeStance Health Group reported Q4 2025 revenue of $382.2 million, an increase of 17%, and full-year 2025 revenue of $1,424.3 million, up 14%.
- For the full year 2025, the company achieved net income of $9.7 million and Adjusted EBITDA of $157.7 million.
- LifeStance generated $146.2 million in net cash provided by operations and $110.0 million in Free Cash Flow for the full year 2025.
- For full year 2026, the company expects revenue between $1.615 billion and $1.655 billion, and Adjusted EBITDA between $185 million and $205 million.
- The Board of Directors has approved a $100 million share repurchase program.
3 days ago
LifeStance Health Group Announces Q4 and Full Year 2025 Results, Initiates Share Repurchase Program, and Provides 2026 Guidance
LFST
Earnings
Guidance Update
Share Buyback
- LifeStance Health Group reported Q4 2025 revenue of $382.2 million (up 17%) and full-year 2025 revenue of $1,424.3 million (up 14%), with net income of $11.7 million in Q4 and $9.7 million for the full year.
- Adjusted EBITDA reached $48.8 million in Q4 2025 and $157.7 million for the full year 2025.
- The company announced a $100 million share repurchase program.
- For full year 2026, LifeStance expects revenue of $1.615 billion to $1.655 billion and Adjusted EBITDA of $185 million to $205 million.
- The clinician base increased 9% to 8,040 clinicians by year-end 2025, supporting 9.0 million visit volumes for the full year.
3 days ago
LFST Reports Strong Q3 2025 Results, Raises Full-Year Adjusted EBITDA Guidance
LFST
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LifeStance Health (LFST) reported strong third-quarter 2025 financial results, with revenue growing 16% year-over-year to $364 million and adjusted EBITDA increasing 31% year-over-year to $40 million, achieving an 11.1% margin which is the highest since going public. The company also achieved positive net income of $1.1 million.
- Operational performance was robust, marked by 17% year-over-year organic visit growth to 2.3 million visits, driven by a record 288 organic net clinician adds and a 5% increase in visits per average clinician.
- For the full year 2025, the company raised its adjusted EBITDA guidance midpoint by $4 million to $146-$152 million, while maintaining its revenue guidance midpoint of $1.41-$1.43 billion.
- Looking ahead to 2026, LifeStance anticipates mid-teens revenue growth driven by low double-digit visit volume increases and low to mid-single-digit rate improvements, with expectations for continued margin expansion and positive net income and earnings per share for the full year.
- The company plans to make additional investments in Q4 2025, which will result in a sequential decrease in Q4 margins, to better position itself for achieving its 2026 growth objectives.
Nov 6, 2025, 1:30 PM
LifeStance Health Reports Q3 2025 Financial Results
LFST
Earnings
Revenue Acceleration/Inflection
- LifeStance Health reported Total Revenue of $363.8 million for Q3 2025.
- The company achieved Adjusted EBITDA of $40.2 million with an 11.1% margin and a Net income of $1.1 million in Q3 2025.
- Center Margin for Q3 2025 was $116.6 million , representing a 32.0% margin.
- Clinician count reached 7,996 , supporting 2,299,000 Total Visits in Q3 2025.
- The company generated Free Cash Flow of $17.0 million and ended Q3 2025 with $203.9 million in cash and cash equivalents.
Nov 6, 2025, 1:30 PM
LifeStance Health Group Reports Strong Q3 2025 Results and Raises FY 2025 Adjusted EBITDA Outlook
LFST
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LifeStance Health Group reported Q3 2025 revenue of $363.8 million, a 16% increase compared to the prior-year period, and achieved net income of $1.1 million.
- Adjusted EBITDA for Q3 2025 grew 31% to $40.2 million, supported by an 11% increase in its clinician base to 7,996 and a 17% rise in visit volumes to 2.3 million.
- The company generated $27.3 million in net cash provided by operations and $17.0 million in Free Cash Flow during Q3 2025, ending the quarter with a cash position of $203.9 million.
- For the full year 2025, LifeStance reiterated its revenue expectations of $1.41 billion to $1.43 billion and raised its Adjusted EBITDA expectations to $146 million to $152 million.
Nov 6, 2025, 11:00 AM
LifeStance Health Group, Inc. Reports Strong Q3 2025 Results and Raises Full-Year Adjusted EBITDA Guidance
LFST
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LifeStance Health Group, Inc. reported revenue of $363.8 million for the third quarter ended September 30, 2025, marking a 16% increase compared to the prior year, and achieved net income of $1.1 million.
- Adjusted EBITDA increased 31% to $40.2 million in Q3 2025, with a Free Cash Flow of $17.0 million.
- The company's clinician base grew 11% to 7,996 clinicians, and visit volumes increased 17% to 2.3 million in the third quarter.
- For the full year 2025, LifeStance reiterated revenue expectations of $1.41 billion to $1.43 billion and raised Adjusted EBITDA expectations to $146 million to $152 million.
Nov 5, 2025, 11:41 PM
Quarterly earnings call transcripts for LifeStance Health Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more